Receives GMP Approval from Taiwan FDA

BEXIMCO PHARMACEUTICALS LTD.

July 4, 2014

Beximco Pharma Becomes First Bangladeshi Company to Receive GMP Approvalfrom Taiwan Food and Drug Administration (TFDA)

Beximco Pharmaceuticals Limited ("BPL" or "the Company"), the fast-growing manufacturer of generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids, today announces that it has received GMP ("Good Manufacturing Practices") accreditation from the Taiwan Food and Drug Administration (TFDA) for its oral solid inhaler and sterile eye drop facilities.

Beximco Pharma is the first Bangladeshi company to receive GMP accreditation from the TFDA, which is considered to be one of the world's most stringent regulatory agencies. This prestigious and notable achievement opens a new marketing opportunity for Beximco Pharma's products in the ASEAN market, including Taiwan, one of the most advanced pharmaceutical markets in Asia. Like several other developed countries, Taiwan is increasingly promoting access to generic drugs, which offers opportunities for generic drug companies like Beximco Pharma. There are currently only a limited number of generic pharmaceutical companies which have received TFDA approval.

This significant milestone validates Beximco Pharma's commitment to expand its business around the globe. The Company currently exports to many countries and its world class manufacturing facilities have already received GMP approvals from global regulatory authorities including AGES (EU), TGA (Australia) and ANVISA (Brazil).

Nazmul Hassan, Managing Director of Beximco Pharma, said; "We are very pleased to have reached such an important milestone with the TFDA, which is testament to the high standards of quality and compliance practices put in place by the Company. This approval is an important step towards our aspiration to become a global generic drug player and building a significant presence in the regulated markets.''

For further information please visit www.beximco-pharma.com or enquire to: 

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 861 9151, ext.20080

Daniel Stewart & Company (NOMAD and Broker)

Emma Earl

Paul Shackleton

Tel: +44 (0)20 7776 6550

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0)20 3727 1000

Notes to Editors

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,000 employees of the Company.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island, Latin & Central American countries, Middle East, Central Asia, South East Asia, including Singapore, Malaysia, Philippines & Hong Kong, and Europe & Austria.